Fig. 2From: Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trialTumor responses in select tumors at the recommended dose (30 mg/kg every 3 weeks). A Best percentage change from baseline in target lesion size. B Tumor responses per RECIST v1.1 over timeBack to article page